Konstantinos Aliazis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Konstantinos Aliazis has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Vassiliki A. Boussiotis
Beth Israel Deaconess Medical Center 18 Department of Hematology Oncology Harvard Medical School, Boston, Massachusetts
27 shared publications - Alain Charest
Beth Israel Deaconess Medical Center
26 shared publications - Alan T. Yeo
Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts
25 shared publications - Christopher Michael Rose
Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
25 shared publications - Frederick S. Varn
The Jackson Laboratory for Genomic Medicine, Farmington, USA
25 shared publications - Hemant Varma
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School
25 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
Supplementary figures & legends
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
Supplementary figures & legends
- Top Cited Papers
- 13 June 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (6) , 924-937
The tumor microenvironment’s role in the response to immune checkpoint blockade
Beyond cancer cells, the tumor microenvironment (TME) includes cells of the innate and adaptive immune systems but also non-immune cells, such as fibroblasts and endothelial cells. Depending on the cues they receive, infiltrating myeloid cells, such as monocytes, macrophages, dendritic cells and neutrophils, perform immune stimulatory or suppressive functions by educating adaptive immune cells, thereby guiding their responses to cancer cells and cancer treatment, such as immune checkpoint blockade (ICB). The increasing understanding that anti-tumor immunity goes beyond T cells with improved functionality, and the unraveling of resistance mechanisms beyond T cell exhaustion, have renewed interest in non-T cell components of the TME to identify novel therapeutic targets and improve ICB responses. Here, we review immune and non-immune cellular components of the TME that regulate adaptive cell responses and their role in ICB response and resistance.
- 13 June 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (6) , 924-937
Top Cited PapersThe tumor microenvironment’s role in the response to immune checkpoint blockade
Beyond cancer cells, the tumor microenvironment (TME) includes cells of the innate and adaptive immune systems but also non-immune cells, such as fibroblasts and endothelial cells. Depending on the cues they receive, infiltrating myeloid cells, such as monocytes, macrophages, dendritic cells and neutrophils, perform immune stimulatory or suppressive functions by educating adaptive immune cells, thereby guiding their responses to cancer cells and cancer treatment, such as immune checkpoint blockade (ICB). The increasing understanding that anti-tumor immunity goes beyond T cells with improved functionality, and the unraveling of resistance mechanisms beyond T cell exhaustion, have renewed interest in non-T cell components of the TME to identify novel therapeutic targets and improve ICB responses. Here, we review immune and non-immune cellular components of the TME that regulate adaptive cell responses and their role in ICB response and resistance.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
Supplementary figures & legends
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
Supplementary figures & legends
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
Supplementary figures & legends
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
Supplementary figures & legends